Prenuvo wants to see your future before it sees you.

§ 01 / Who They Are NowInside the tube

It is 7:42 a.m. in Redwood City and a 41-year-old marketing executive is sliding into a Siemens magnet on her lunch hour. She is not sick. That is the point. Sixty minutes from now she will walk out with a report flagging more than five hundred possible findings - or, much more likely, a clean bill of health and a heat-mapped portrait of her own anatomy. She will then go to a salad place. This is Prenuvo's pitch in one beautifully ordinary scene.

Prenuvo is, on paper, a network of preventive-medicine clinics. In practice it is something stranger: a consumer brand selling a radiologist's tool, a Webflow-fronted health business with an Apollo email and a tech stack that includes Salesforce Health Cloud, Databricks, dbt, GraphQL and a tasteful amount of React. It looks like a startup. It runs like a hospital. It markets like a sneaker drop.

By late 2025 the company says it has run more than 150,000 of its 60-minute whole-body MRI exams, opened 27 clinics across North America, Australia and now London, and raised $120 million in a Series B co-led by Forerunner Ventures, Left Lane Capital and Felicis. Annual revenue is reportedly somewhere around the nine-figure mark. None of which would matter if the proposition itself were boring. It is not.

§ 02 / The Problem They SawMedicine that waits

American healthcare is, by design, reactive. Insurance covers the catastrophe, not the warning. The system pays you to find cancer late, then bills you generously for the privilege of treating it. You do not need a manifesto to see the absurdity here; you just need a deductible.

Whole-body MRI has existed for decades as a research and clinical tool. It is also expensive, slow, and historically built for sick people who already had a reason to lie inside a magnet for two hours. The technology was excellent. The user experience was not. The economics were worse.

The orthodox medical view of preventive whole-body MRI is, to put it politely, unimpressed. The American College of Radiology has stated there is insufficient evidence to recommend whole-body screening for asymptomatic patients, citing false positives and the cascade of follow-up tests that come with them. It is a real critique. Prenuvo does not dodge it; the company has built a research arm and a publication trail specifically to engage it. You can think of this as a long-running argument between a startup and a profession, conducted partly in journals and partly on Instagram.

§ 03 / The Founders' BetFrom Tap Tap Revenge to tumors

Andrew Lacy is not a doctor. He is a former McKinsey consultant who co-founded Tapulous, the iPhone game studio behind Tap Tap Revenge, sold the company to Disney, and then, by his own account, walked into a whole-body MRI as a patient and came out with the idea of his career. The story has the convenient symmetry of a TED talk. It also happens to be true.

His co-founder, Dr. Raj Attariwala, is a radiologist and biomedical engineer who had spent years refining an unusually fast whole-body protocol on a single magnet in Vancouver. Lacy brought the consumer instincts; Attariwala brought the physics. The bet was that, with software and standardization, the long, awkward, hospital-grade scan could become a one-hour appointment a non-sick person would actually book.

§ 04 / The ProductOne hour, no radiation, 2,000 images

The core product is straightforward enough to fit on a billboard: a 60-minute whole-body MRI, no radiation, no contrast dye, screened against more than 500 potential findings, from solid tumors and aneurysms to metabolic and autoimmune red flags. The price is around $2,499 in the U.S. for a standalone scan, with bundled memberships above that.

What is actually under the hood is less billboard-friendly and more interesting. Prenuvo standardizes its imaging protocols across Siemens and GE Healthcare scanners, pipes the data through Sectra PACS, then layers its own software - including FDA-cleared body composition AI - on top of radiologist review. The 2025 launch of Prenuvo Enhanced pulled in advanced blood biomarker testing and clinical follow-up, nudging the company from a one-off scan toward a longitudinal health relationship.

A 60-minute scan that yields roughly 2,000 images. Your annual physical, by comparison, is a clipboard.

§ 05 / ReceiptsEight years, marked up

§ 06 / The ProofWhat the numbers actually say

Prenuvo's own published statistic - the one repeated in its founder interviews and investor decks - is that between roughly 2% and 5% of its scanned patients are alerted to a potentially serious finding. That is a wide range. It is also, depending on which radiologist you ask, either a public-health revolution or a false-positive factory. The truth is almost certainly an unsatisfying mix of both, sharpened year over year by data.

The partner stack is sober: Siemens and GE Healthcare for hardware, Sectra for imaging workflow, Auth0 and Salesforce Health Cloud holding the consumer side together. There is also a quietly serious data operation - Databricks, dbt, Fivetran, Looker - which is essentially the apparatus you need if you intend to argue with radiologists with receipts instead of vibes.

§ 07 / The MissionBoring as a strategy

The most subversive thing about Prenuvo's mission is how unsexy it is. Make whole-body screening routine. Not heroic. Not biohacking. Not a moonshot. Just normal - the way teeth cleanings are normal, the way oil changes are normal, the way checking your phone screen for cracks is now part of the ritual of owning a phone. The company's bet is that, given a calmer cadence and a believable price, prevention becomes a habit instead of an event.

The cultural pushback is structural, not personal. Influencer endorsements and celebrity selfies have made Prenuvo look, to skeptics, like a wellness product wearing a lab coat. The company would argue the opposite is true: that it is using the cultural surface area of a brand to introduce a deeply clinical idea to people whose insurance plans would otherwise never offer it. Both arguments can be partially right. That is how new categories usually feel.

§ 08 / Why It Matters TomorrowThe long bet

The interesting question is not whether Prenuvo will continue to grow. With 27 clinics, a London beachhead, employer-sponsored channels and an enthusiastic investor base, growth is the easy part. The harder question is whether the company can do what every new healthcare category has to do eventually: turn its consumer-paid traction into clinical evidence robust enough that the next decade's guidelines have to mention it.

If they pull it off, the legacy will not be the celebrity endorsements or the press releases or even the magnet. It will be a quiet shift in what counts as a normal year of being a person: a blood test, a workout, a scan, a follow-up. If they don't, the criticism will be loud and the lessons will still be useful - because the system that bills you only after you are sick is not, by any honest measure, the system you wanted in the first place.

§ 09 / The Scene, RevisitedBack to Redwood City

It is 8:46 a.m. The marketing executive is back in her car. Her phone is buzzing with a calendar reminder for a follow-up appointment to discuss her results in two weeks. She does not know yet whether the scan found anything. She knows the report is being read by a radiologist who has reviewed thousands of these. She knows the images will sit in her chart year over year, so the next scan can be compared to this one, and the one after that to the one before. She knows, in short, where her own baseline lives.

That is the actual product. The magnet is the marketing. The baseline is the bet.

§ 10 / Watch & ReadIf you want to keep going